السوق العالمية لأدوية علاج سرطان العين – اتجاهات الصناعة والتوقعات حتى عام 2028

تحليل السوق والرؤى: سوق أدوية علاج سرطان العين العالمي

من المتوقع أن ينمو سوق دواء سرطان العين بمعدل محتمل قدره 7.0٪ في الفترة المتوقعة من 2021 إلى 2028. إن الزيادة في الاستثمار في البحث والتطوير هي العامل المسؤول عن نمو السوق.

الورم الميلانيني في العين هو عمومًا سرطان ثانوي، ويبدأ في مكان مختلف في الجسم وينتشر إلى العين. الورم الميلانيني في العين هو نوع من السرطان يتطور في خلايا العين التي تنتج الميلانين. يحدث عمومًا في منتصف الطبقات الثلاث.

من المتوقع أن يؤدي الارتفاع السريع في انتشار سرطان العين إلى تسريع نمو السوق في الفترة المتوقعة من 2021 إلى 2028. وبالمثل، من المتوقع أيضًا أن يؤدي ارتفاع حالات الإصابة بالأمراض المستهدفة في جميع أنحاء العالم والارتفاع السريع في عدد السكان المسنين إلى تعزيز نمو سوق أدوية سرطان العين. علاوة على ذلك، من المتوقع أيضًا أن يؤدي التطوير السريع للعوامل الجديدة والعلاج المركب مع آثار جانبية أقل وبقاء أفضل وزيادة التركيز على الطب الشخصي إلى دفع معدل نمو السوق.

بالإضافة إلى ذلك، من المرجح أن يؤدي ارتفاع نفقات الرعاية الصحية وزيادة نفقات الرعاية الصحية في البلدان النامية وزيادة الاستثمارات في البحث والتطوير السريع من قبل اللاعبين الرئيسيين إلى خلق العديد من الفرص الجديدة التي ستؤثر على نمو سوق دواء سرطان العين في الفترة المتوقعة من 2021 إلى 2028.

ومع ذلك، من المتوقع أن يعمل الافتقار إلى الوعي والتشخيصات العالية كعائقين رئيسيين أمام نمو سوق أدوية سرطان العين، في حين أن تكاليف الإجراءات الجراحية المرتفعة يمكن أن تشكل تحديًا لنمو السوق المستهدفة في فترة التنبؤ المذكورة أعلاه.

This eye melanoma drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the eye melanoma drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Eye Melanoma Drug Market Scope and Market Size

Eye melanoma drug market is segmented on the basis of infected site, diagnosis, treatment, mechanism of action, drugs type, route of administration and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• Based on infected site, the eye melanoma drug market can be segmented into sclera, retina and uvea.
• On the basis of diagnosis, the eye melanoma drug market can be segmented intoeye exam, eye ultrasound, angiogram, optical coherence tomography and biopsy.
• On the basis of treatment, the eye melanoma drug market can be segmented intoradiation therapy, laser treatment, photodynamic therapy, cryotherapy and surgery.
• On the basis of mechanism of action, the eye melanoma drug market can be segmented into targeted drugs and immunotherapy drugs.
• On the basis of drugs type, the eye melanoma drug market can be segmented intopembrolizumab, ipilimumab, dacarbazine, temozolomide, and others.
• The route of administration segment of theeye melanoma drug market can be segmented intooraltopical, intravenous and others.
• On the basis of end users, theeye melanoma drug market can be segmented into hospitals, homecare, specialty clinics and others.

Eye Melanoma Drug Market Country Level Analysis

Eye melanoma drug market is analyzed and market size information is provided by country by infected site, diagnosis, treatment, mechanism of action, drugs type, route of administration and end users as referenced above.

The countries covered in the eye melanoma drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the eye melanoma drug market due to the strongpresence of a well-developed healthcare sector and huge patient population. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the strongpresence of a huge patient population, constantly developing economies and rise in the healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Eye melanoma drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Eye Melanoma Drug Market Share Analysis

Eye melanoma drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to eye melanoma drug market.

The major players covered in the eye melanoma drug market report are Merck & Co., Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc, Sanofi, AbbVie Inc, Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Johnson & Johnson Services, Inc, Carl Zeiss AG, Takeda Pharmaceutical Company Limited, Siemens, Koninklijke Philips N.V, Castle Biosciences, Inc, Spectrum Pharmaceuticals, Inc,Teva Pharmaceutical Industries Ltd., and Gilead Sciences, Inc., among other domestic and global players. Eye melanoma drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-44970